Sunday, November 18

WSJ: Rember Tackles the Tau behind Alzheimer's


Watch this Wall Street Journal interview on why Dr. Wischik sees tau as a more worthwhile anti-Alzheimer's target than plaque. Learn more about TauRx' Alzheimer's trial drug called Rember.

WSJ's Shirley Wang spoke with Dr. Wischik about his work on this new drug to treat the devastating disease.

Comment or Share:

Post a Comment

Your comments (up to 200 words):